RMD Stock Recent News

I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will have little effect on the Company.

Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.

ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow significantly in the coming years. Despite being down, the stock has rebounded and is expected to continue gaining in the future.

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed's shares have fallen 37% due to struggles with profitability and investor fears of weight loss drugs, but I believe in its long-term potential. The company reported a 16% increase in revenue and strong demand for its products, but margins were a concern. ResMed's three-pillar strategy and market outlook remain robust, and it has a solid balance sheet and healthy cash flow.

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.

ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer Conference Call Participants David Bailey - Macquarie David Low - JPMorgan Dan Hurren - MST Chris Cooper - Goldman Sachs Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margarette Kaczor - William Blair Steve Wheen - Jarden Saul Hadassin - Barrenjoey Capital Matthew Chevrier - Citi Operator Hello, and welcome to the ResMed First Quarter Fiscal Year 2024 Earnings Conference Call and Webcast [Operator Instructions]. As a reminder, this conference is being recorded.